Treatment of Colorectal Liver Metastases With Immunotherapy and Bevacizumab

Summary

Liver is the most common site of metastases from colorectal cancer. Neoadjuvant chemotherapy with targeted agents is usually recommended for borderline-resectable liver metastases that are technically difficult to resect for conversion to resectable disease and control of metastatic spread. However, the prognosis of these patients are still poor, and long term disease-free survival over 3 years is rare and \<20%. More effective measures to prevent recurrence are needed before or after resection of colorectal liver metastases.

Timeline

Start

2019-05-15

Primary completion

2021-12-22

Completion

2023-10-24

Publications

• Kim W, Kim JE, Hong YS, Hwang DW, Kim J, Lee JS, Shin JH, Kim TW, Nagarkar D, Byrd A, Sung CO, Kim SY. Dynamics of tumor ecosystems and microbiome in response to neoadjuvant ABFOLFOX treatment in patients with unresectable colorectal cancer with liver metastasis. Genome Med. 2026 May 30. doi: 10.1186/s13073-026-01680-4. Online ahead of print.

Drugs

Indications